Sign in
CompletedPhase 4

CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly

Key facts

Who runs it
Peking Union Medical College Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
86 people enrolled
Started
15 Sept 2023
Ended
27 Feb 2025
Type of study
Interventional, 2 groups
Treatments tested
  • Ciclosporin
  • Avatrombopag
  • Anti-Human Thymocyte Immunoglobulin, Rabbit
Record updated
30 April 2025

Who can take part

Age
60 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Patients with newly diagnosed severe aplastic anemia, aged greater than 60 years
  • Patients met the diagnostic criteria of severe aplastic anemia (SAA)
  • Complete all screening assessments as outlined in the test protocol
  • Without or with no more than 1 month treatment of ciclosporine, tacrolimus, glucocortocoid, or TPO-RAs
  • Agree to sign the informed consent form

Who cannot take part

  • Patients with previous history of hematopoietic stem cell transplantation
  • Patients with previous history of thrombosis in 1 year
  • Patients with concurrent malignancy
  • Known diagnosis of congenital hematopoietic failure disorders (e.g. Fanconi anemia) and other causes of cytopenia
  • Patients with uncontrolled bleeding and/or infection despite standard treatment
  • Patients with severe heart, liver or renal disease
  • Abnormal renal function: creatinine > 1.2 normal upper limit, albumin < 0.9 normal lower limit, or CLcr < 30 ml/min
  • Abnormal liver function: transaminase > 2.5 normal upper limit, or tota bilirubin > 2.5 normal upper limit
  • Those who are considered unsuitable for enrollment by the investigator

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter, prospective, randonmized study. Our previous retrospective study showed that for SAA patients who were intolerant to ATG, CsA+ eltrombopag (EPAG) had similar efficacy to CsA+ATG+EPAG. Since the action mechanism of AVA and EPAG is not exactly the same, and the metabolic level of the elderly is not the same as that of younger patients, it is unknown whether there are predictive factors of efficacy in the treatment of AVA. We wondered whether CsA+AVA could achieve an efficacy similar to CsA+ATG+AVA in the Elderly. Meanwhile, to explore the predictive factors of efficacy, to find out a safe and effective treatment strategy for the Elderly.

The 2 groups in the trial

  • CsA+ATG+AVATreatment being tested

    Ciclosporine: 3-5 mg/kg/d orally, with ciclosporine trough concentrations maintained at 100-200 ng/ml for 3 months to achieve maximum efficacy and then tapered; Anti-human thymocyte: rabbit anti-human thymocyte globulin (r-ATG 3mg/kg/d) was administered intravenously for 5 days; Avatrombopag:60 mg/d orally, for a total of 24 weeks. Adjust the dose according to the platelet counts of patients.

    Treatment: Ciclosporin, Avatrombopag, and Anti-Human Thymocyte Immunoglobulin, Rabbit

  • CsA+AVATreatment being tested

    Ciclosporine: 3-5 mg/kg/d orally, with ciclosporine trough concentrations maintained at 100-200 ng/ml for 3 months to achieve maximum efficacy and then tapered; Avatrombopag:60 mg/d orally, for a total of 24 weeks. Adjust the dose according to the platelet counts of patients.

    Treatment: Ciclosporin and Avatrombopag

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Ciclosporin + Antithymocyte Immunoglobulin + Avatrombpag Versus Ciclosporin + Avatrombpag for the Treatment of Severe Aplastic Anemia in the Elderly
Record updated
30 April 2025